EMA Authorised: Exforge HCT (valsartan;hydrochlorothiazide;amlodipine besilate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Exforge HCT, a fixed-dose combination of valsartan, hydrochlorothiazide, and amlodipine besilate, for the treatment of hypertension. The mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Novartis Europharm Limited. Decision date: 05/02/2026